Immune Checkpoint Therapy and Biomarker in Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 6700
Special Issue Editor
Interests: the role of nanomedicine and immunotherapy; cancer diagnosis, imaging, and therapy; pharmaceutical sciences; nanotechnology; drug delivery; immunotherapy; cancer research; imaging and theranostics; pharmaceutical biotechnology
Special Issue Information
Dear Colleagues,
Immune checkpoint therapy such as CTLA-4 or PD-1/PD-L1 immune checkpoint inhibitors (ICPs), chemoimmunotherapy, and CART therapy have revolutionized cancer treatment by harnessing the power of the immune system to fight cancer. The therapy works by blocking the checkpoint proteins that cancer cells use to evade the immune system. This allows the immune system to attack and kill cancer cells, which can lead to long-term remission and potentially a cure. However, not all patients respond to this therapy, and identifying the right patients is vital to ensure the best possible outcomes. This is where biomarkers come in. Biomarkers are measurable indicators that can help predict the likelihood of a patient responding to a particular therapy. In the case of immune checkpoint therapy, biomarkers can help to identify patients who are most likely to benefit from the therapy, but they can also be used to monitor a patient's response to therapy.
New translational and clinical research on immune checkpoint therapy and biomarkers holds great promise for the treatment of different types of cancer. By identifying the right patients and monitoring their response to therapy, clinicians can ensure that patients receive the most effective treatment possible. As research in this area continues, our goal in this Special Issue is to collect papers on the advances in the field of cancer immunotherapies especially Immune checkpoints (ICPs) and their biomarkers.
Dr. Hashem O. Alsaab
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immune-checkpoint inhibitors
- chemoimmunotherapy
- immunotherapy
- cancer
- tumor microenvironment
- immune biomarker